scholarly journals COVID ‐19: Topical agents and therapeutic prevention of nasal viral acquisition

2020 ◽  
Author(s):  
Shaden Abdelhadi ◽  
Zbigniew Ruszczak ◽  
Robert A. Schwartz
Keyword(s):  
Therapeutic Prevention

Mental health: Therapeutic prevention

2015 ◽  
Vol 3 (1) ◽  
pp. 58-58 ◽  
Author(s):  
Dame Sarah Cowley
Keyword(s):  
Mental Health ◽  
Therapeutic Prevention

scholarly journals Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Cai-Mei Zheng ◽  
Kuo-Cheng Lu ◽  
Chia-Chao Wu ◽  
Yung-Ho Hsu ◽  
Yuh-Feng Lin
Keyword(s):  
Risk Factors ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Vascular Calcification ◽  
Cardiovascular Complications ◽  
Serum Phosphate ◽  
Related Factors ◽  
Therapeutic Prevention ◽  
Esrd Patients

Vascular calcification is common in ESRD patients and is important in increasing mortality from cardiovascular complications in these patients. Hyperphosphatemia related to chronic kidney disease is increasingly known as major stimulus for vascular calcification. Hyperphosphatemia and vascular calcification become popular discussion among nephrologist environment more than five decades, and many researches have been evolved. Risk factors for calcification are nowadays focused for the therapeutic prevention of vascular calcification with the hope of reducing cardiovascular complications.

scholarly journals THER-07. DEVELOPMENT OF A NEW MOLECULAR PREDICTOR FOR RISK OF BRAIN METASTASES AND EFFICACY OF TARGETED THERAPY IN MELANOMA

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i12-i12
Author(s):  
Howard Colman ◽  
Ken Boucher ◽  
Chris Stehn ◽  
David Kircher ◽  
Sheri Holmen
Keyword(s):  
Targeted Therapy ◽  
Brain Metastases ◽  
Predictive Power ◽  
Data Set ◽  
Multiple Gene ◽  
Methods Development ◽  
Melanoma Patients ◽  
Therapeutic Prevention ◽  
Screening Trial ◽  
Molecular Predictor

Abstract Despite therapeutic advances in the treatment of melanoma, development of brain metastases (BM) continues to be a major manifestation of treatment failure. The ability to identify those patients who are at highest risk of developing brain metastases is limited with current methods. Development of sensitive and specific biomarkers to predict which stage II-III melanoma patients are at highest risk of BM would enable initiation of prospective clinical trials focused on both intensive surveillance and therapeutic prevention. To accomplish this goal, we embarked on an effort to optimize a combined molecular/clinical/pathologic predictor of BM risk. We firstanalyzed multiple gene expression datasets including TCGA (n = 437) and an independent series from Australia (n = 183) and identified a list of 60 consensus genes that is robustly predictive of development of melanoma BM (p < 0.05; FDR 5%). Next, we performed a similar analysis of association of miRNAs and melanoma BM risk which identified a set of miRNAs with significant predictive power. An optimized combined set of mRNA and miRNA markers was a better predictor of BM risk than either mRNA or miRNA list alone when applied to the TCGA data set. The combined predictor was most sensitive in separating patients with no metastases from those with either BM or systemic metastases. Current efforts are focused on optimizing miRNA and mRNA separation of patients specifically with BM from those with other mets, and with integrating the expression classifier with other clinical and pathologic predictive factors including: age, stage, thickness, location, histology, ulceration, gender. The sensitivity and specificity of the resulting clinical/molecular predictor will be validated in an independent retrospective cohort, and subsequently implemented in a prospective BM screening trial to determine real-world utility of this approach in preparation for prospective BM adjuvant/chemoprevention trials utilizing both immunotherapy and targeted therapy approaches.

scholarly journals A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene

2017 ◽  
Vol 11 (1) ◽  
pp. 38-43 ◽  
Author(s):  
Silvia Noonan ◽  
Ambra Pasa ◽  
Vincenzo Fontana ◽  
Silvia Caviglia ◽  
Bernardo Bonanni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Specialists ◽  
Therapeutic Prevention

Therapeutic prevention of ischemia following intraarterial barbiturate injection

1977 ◽  
Vol 22 (1) ◽  
pp. 46-53 ◽  
Author(s):  
H.M. Lazarus ◽  
W. Hutto ◽  
D.G. Ellertson
Keyword(s):  
Therapeutic Prevention

scholarly journals A Comparative High-Throughput Screening Protocol to Identify Entry Inhibitors of Enveloped Viruses

2013 ◽  
Vol 19 (1) ◽  
pp. 100-107 ◽  
Author(s):  
Juan Wang ◽  
Han Cheng ◽  
Kiira Ratia ◽  
Elizabeth Varhegyi ◽  
William G. Hendrickson ◽  
...  
Keyword(s):  
High Throughput ◽  
Viral Entry ◽  
High Throughput Screening ◽  
Marburg Virus ◽  
Lassa Virus ◽  
Viral Pathogens ◽  
Enveloped Viruses ◽  
Entry Inhibitors ◽  
Screening Protocol ◽  
Therapeutic Prevention

Emerging and reemerging human viral pathogens pose great public health concerns since therapeutics against these viruses are limited. Thus, there is an urgent need to develop novel drugs that can block infection of either a specific virus or a number of viruses. Viral entry is thought to be an ideal target for potential therapeutic prevention. One of the challenges of developing antivirals is that most of these viruses are highly pathogenic and therefore require high biosafety-level containment. In this study, we have adopted a comparative high-throughput screening protocol to identify entry inhibitors for three enveloped viruses (Marburg virus, influenza virus H5N1, and Lassa virus) using a human immunodeficiency virus–based pseudotyping platform. We demonstrate the utility of this approach by screening a small compound library and identifying putative entry inhibitors for these viruses. One major advantage of this protocol is to reduce the number of false positives in hit selection, and we believe that the protocol is useful for inhibitor screening for many enveloped viruses.

scholarly journals Gasotransmitters for the Therapeutic Prevention of Hypertension and Kidney Disease

2021 ◽  
Vol 22 (15) ◽  
pp. 7808
Author(s):  
Chien-Ning Hsu ◽  
You-Lin Tain
Keyword(s):  
Nitric Oxide ◽  
Kidney Disease ◽  
Therapeutic Potential ◽  
Current Knowledge ◽  
Current Evidence ◽  
Developmental Origins ◽  
Developing Kidney ◽  
Prevention Of Hypertension ◽  
Therapeutic Prevention ◽  
In Pregnancy

Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S), three major gasotransmitters, are involved in pleiotropic biofunctions. Research on their roles in hypertension and kidney disease has greatly expanded recently. The developing kidney can be programmed by various adverse in utero conditions by so-called renal programming, giving rise to hypertension and kidney disease in adulthood. Accordingly, early gasotransmitter-based interventions may have therapeutic potential to revoke programming processes, subsequently preventing hypertension and kidney disease of developmental origins. In this review, we describe the current knowledge of NO, CO, and H2S implicated in pregnancy, including in physiological and pathophysiological processes, highlighting their key roles in hypertension and kidney disease. We summarize current evidence of gasotransmitter-based interventions for prevention of hypertension and kidney disease in animal models. Continued study is required to assess the interplay among the gasotransmitters NO, CO, and H2S and renal programming, as well as a greater focus on further clinical translation.

Sign in / Sign up

Export Citation Format

Share Document